Current Journal of Neurology

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Peer Review Process

Journal Metrics

News

Publication Ethics and Malpractice Statement

The effect of interferon beta on quality of life in patients with multiple sclerosis: A systematic review and meta-analysis study

Articles in Press

Document Type : Review Article

Authors

1 Department of Anesthesiology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran

2 Nargund College of Physiotherapy, Rajiv Gandhi University of Health Sciences, Bangalore, India

3 School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

4 Student Research Committee, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran

5 Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan

6 Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

7 Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Science, Tehran, Iran

8 School of Medicine, Yazd Branch, Islamic Azad University, Yazd, Iran

9 School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Background: Multiple sclerosis (MS) is one of the most common progressive neurological disorders affecting young adults. This study aimed to perform a meta-analysis on the effect of interferon beta (IFN-β) on the quality of life (QOL) of patients with MS.
Methods: Using valid keywords and searching through databases like Medlib, ScienceDirect, PubMed, etc., 10 articles published between 1999 and 2020 were collected. The inclusion criteria were developed based on clinical guidelines, focusing on studies involving adults with MS treated with IFN-β, with outcomes measuring QOL. The exclusion criteria included studies not in English, those involving pediatric populations, or those lacking a control group. In the reviewed studies, 14 scales of QOL were measured at the beginning and the end of treatment with IFN-β. 
The data were analyzed using the random effects model meta-analysis method with R software and Stata software. Publication bias was not significant. Heterogeneity was evaluated using the Q test and the I2 index. In heterogeneous studies, subgroup analysis and meta-regression were used for meta-analysis. The random-effect model was used for analyses with I2 of more than 50%.
Results: A total number of 1320 people with an average age of 32.40 ± 8.77 years were included in this study. On average, there was a slight decline in energy and satisfaction with sexual function scales (SSF), while a slight improvement was seen in the other 12 scales, following the treatment with IFN-β. However, no significant changes were observed in any QOL scales following treatment, except for health distress (HD) (P < 0.001), role limitation due to physical problems (RLPP) (P < 0.001), and role limitation due to emotional problems (RLEP) (P = 0.037), which showed a slight yet considerable improvement. The physical and mental components, showed significant increases of 0.189 [95% Confidence interval (CI): 0.083, 0.295, I2 = 0%] and 0.221 (95% CI 0.119, 0.324, I2 = 0%) in the scores after using IFN-β, respectively.
Conclusion: This study's results showed that treatment with IFN-β does not negatively affect the QOL of patients with MS. Moreover, this treatment can slightly improve most QOL scales associated with the disability observed in MS.

Keywords

Main Subjects

References
  1. Fletcher SG, Castro-Borrero W, Remington G, Treadaway K, Lemack GE, Frohman EM. Sexual dysfunction in patients with multiple sclerosis: A multidisciplinary approach to evaluation and management. Nat Clin Pract Urol 2009; 6(2): 96-107.
  2. Mahmoodi GH, Nasiri E, Niaz Azari K. Evaluating mental (Psychological) health in MS patients from Mozandran Province in 1386 (2007). J Mazandaran Univ Med Sci 2009; 18(68): 70-3.
  3. World Health Organization and Multiple Sclerosis International Federation. Atlas: multiple sclerosis resources in the world 2008. Geneva, Switzerland: World Health Organization; 2008.
  4. Rudick RA, Miller D, Clough JD, Gragg LA, Farmer RG. Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis. Arch Neurol 1992; 49(12): 1237-42.
  5. Pakniya N, Bahmani B, Dadkhah A, Azimian M, Naghiyaee M, MasudiSani R. Effectiveness of cognitive existential approach on decreasing demoralization in women with multiple sclerosis. Iranian Rehabilitation Journal 2015; 13(4): 28-33. [In Persian].
  6. Abedini M, Paksersht M, Rafiei A, Valadan R, Amjadi O, Khajavi R, et al. Demographic and clinical characteristics of multiple sclerosis. J Mazandaran Univ Med Sci 2016; 25(132): 13-22. [In Persian].
  7. Morgante L. Hope in multiple sclerosis: A nursing perspective. Int J MS Care 2000; 2(2): 9-15.
  8. Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult Scler 1999; 5(4): 251-9.
  9. Motl R, Mcauley E, Snook E. Physical activity and quality of life in multiple sclerosis: possible roles of social support, self-efficacy, and functional limitations. Rehabilitation Psychology 2007; 52: 143-51.
  10. Janssens AC, van Doorn PA, de Boer JB, Kalkers NF, van der Meche FG, Passchier J, et al. Anxiety and depression influence the relation between disability status and quality of life in multiple sclerosis. Mult Scler 2003; 9(4): 397-403.
  11. Bonomi AE, Patrick DL, Bushnell DM, Martin M. Validation of the United States' version of the World Health Organization Quality of Life (WHOQOL) instrument. J Clin Epidemiol 2000; 53(1): 1-12.
  12. Idiman E, Uzunel F, Ozakbas S, Yozbatiran N, Oguz M, Callioglu B, et al. Cross-cultural adaptation and validation of multiple sclerosis quality of life questionnaire (MSQOL-54) in a Turkish multiple sclerosis sample. J Neurol Sci 2006; 240(1-2): 77-80.
  13. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995; 4(3): 187-206.
  14. Gold SM, Heesen C, Schulz H, Guder U, Monch A, Gbadamosi J, et al. Disease specific quality of life instruments in multiple sclerosis: validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS). Mult Scler 2001; 7(2): 119-30.
  15. Miller A, Dishon S. Health-related quality of life in multiple sclerosis: The impact of disability, gender and employment status. Qual Life Res 2006; 15(2): 259-71.
  16. Khodaveisi M, Rahmati M, Falahinia G, Karami M, Molavi Vardanjani M. The Effect of Orem's Self Care Model on physical quality of life in patients with multiple sclerosis. Scientific Journal of Nursing, Midwifery and Paramedical Faculty 2018; 3(4): 24-35. [In Persian].
  17. Casetta I, Riise T, Wamme NM, Economou NT, De Gennaro R, Fazio P, et al. Gender differences in health-related quality of life in multiple sclerosis. Mult Scler 2009; 15(11): 1339-46.
  18. Javed A, Reder AT. Therapeutic role of beta-interferons in multiple sclerosis. Pharmacol Ther 2006; 110(1): 35-56.
  19. Rudick RA, Goelz SE. Beta-interferon for multiple sclerosis. Exp Cell Res 2011; 317(9): 1301-11.
  20. Cohan SL, Hendin BA, Reder AT, Smoot K, Avila R, Mendoza JP, et al. Interferons and multiple sclerosis: lessons from 25 years of clinical and real-world experience with intramuscular interferon beta-1a (Avonex). CNS Drugs 2021; 35(7): 743-67.
  21. Patti F, Pappalardo A, Montanari E, Pesci I, Barletta V, Pozzilli C. Interferon-beta-1a treatment has a positive effect on quality of life of relapsing-remitting multiple sclerosis: results from a longitudinal study. J Neurol Sci 2014; 337(1-2): 180-5.
  22. Goodin DS, Traboulsee A, Knappertz V, Reder AT, Li D, Langdon D, et al. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon beta-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry 2012; 83(3): 282-7.
  23. Nortvedt MW, Riise T, Myhr KM, Nyland HI. Quality of life in multiple sclerosis: measuring the disease effects more broadly. Neurology 1999; 53(5): 1098-103.
  24. De Giglio L, Marinelli F, Barletta VT, Pagano VA, De Angelis F, Fanelli F, et al. Effect on cognition of estroprogestins combined with interferon beta in multiple sclerosis: Analysis of secondary outcomes from a randomised controlled trial. CNS Drugs 2017; 31(2): 161-8.
  25. Simone IL, Ceccarelli A, Tortorella C, Bellacosa A, Pellegrini F, Plasmati I, et al. Influence of interferon beta treatment on quality of life in multiple sclerosis patients. Health Qual Life Outcomes 2006; 4: 96.
  26. Arnoldus JH, Killestein J, Pfennings LE, Jelles B, Uitdehaag BM, Polman CH. Quality of life during the first 6 months of interferon-beta treatment in patients with MS. Mult Scler 2000; 6(5): 338-42.
  27. Mokhber N, Azarpazhooh A, Orouji E, Khorram B, Modares GM, Kakhi S, et al. Therapeutic effect of Avonex, Rebif and Betaferon on quality of life in multiple sclerosis. Psychiatry Clin Neurosci 2015; 69(10): 649-57.
  28. Jongen PJ, Sindic C, Carton H, Zwanikken C, Lemmens W, Borm G. Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after
    2 years of treatment with intramuscular interferon-beta-1a. J Neurol 2010; 257(4): 584-9.
  29. Vermersch P, de Seze J, Delisse B, Lemaire S, Stojkovic T. Quality of life in multiple sclerosis: influence of interferon-beta1 a (Avonex) treatment. Mult Scler 2002; 8(5): 377-81.
  30. Abolfazli R, Hosseini A, Gholami K, Javadi MR, Torkamandi H, Emami S. Quality of life assessment in patients with multiple sclerosis receiving interferon beta-1a: A comparative longitudinal study of Avonex and Its Biosimilar CinnoVex. ISRN Neurol 2012; 2012: 786526.
  31. Pakdaman H, Amini HA, Gharagozli K, Abbasi M, Tabassi A, Ashrafi F, et al. Health-related quality of life in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon beta-1a in Iran. Int J Neurosci 2017; 127(6): 501-7.
  32. Zecca C, Pavelek Z, Prikrylova K, Ghielmetti M, Beeler A, Gobbi C. Tolerability, treatment satisfaction and quality of life outcomes in stable multiple sclerosis patients switched from injectable therapies to auto injected intramuscular interferon beta 1a: The SFERA study. Mult Scler Relat Disord 2019; 30: 104-9.
  33. Freeman JA, Thompson AJ, Fitzpatrick R, Hutchinson M, Miltenburger C, Beckmann K, et al. Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life. Neurology 2001; 57(10): 1870-5.
  34. Rice GP, Oger J, Duquette P, Francis GS, Belanger M, Laplante S, et al. Treatment with interferon beta-1b improves quality of life in multiple sclerosis. Can J Neurol Sci 1999; 26(4): 276-82.
  35. Burden of illness of multiple sclerosis: Part II: Quality of life. The Canadian Burden of Illness Study Group. Can J Neurol Sci 1998; 25(1): 31-8.
  36. Benedict RH, Wahlig E, Bakshi R, Fishman I, Munschauer F, Zivadinov R, et al. Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci 2005; 231(1-2): 29-34.
  37. Zivadinov R, Zorzon M, Tommasi MA, Nasuelli D, Bernardi M, Monti-Bragadin L, et al. A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. J Neurol Sci 2003; 216(1): 113-8.
  38. Tepavcevic DK, Pekmezovic T, Drulovic J. Quality of life assessment in patients with multiple sclerosis. Vojnosanit Pregl 2009; 66(8): 645-50. [In Serbian].
  39. Rudick RA, Miller DM. Health-related quality of life in multiple sclerosis: Current evidence, measurement and effects of disease severity and treatment. CNS Drugs 2008; 22(10): 827-39.
  40. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59(5): 679-87.
  41. Lily O, McFadden E, Hensor E, Johnson M, Ford H. Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment. Mult Scler 2006; 12(6): 808-13.
  42. Putzki N, Fischer J, Gottwald K, Reifschneider G, Ries S, Siever A, et al. Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis. Eur J Neurol 2009; 16(6): 713-20.
  43. Bermel RA, Weinstock-Guttman B, Bourdette D, Foulds P, You X, Rudick RA. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: A 15-year follow-up study. Mult Scler 2010; 16(5): 588-96.
  44. Filipi M, Jack S. Interferons in the Treatment of Multiple Sclerosis: A Clinical Efficacy, Safety, and Tolerability Update. Int J MS Care 2020; 22(4): 165-72.
  45. Rommer PS, Milo R, Han MH, Satyanarayan S, Sellner J, Hauer L, et al. Immunological aspects of approved MS therapeutics. Front Immunol 2019; 10: 1564.
  46. Jakimovski D, Kolb C, Ramanathan M, Zivadinov R, Weinstock-Guttman B. Interferon beta for multiple sclerosis. Cold Spring Harb Perspect Med 2018; 8(11).
  47. Mokhber N, Azarpazhooh A, Orouji E, Rao SM, Khorram B, Sahraian MA, et al. Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: A randomized clinical trial. J Neurol Sci 2014; 342(1-2): 16-20.
  48. Centonze D, Fantozzi R, Buttari F, Grimaldi LME, Totaro R, Corea F, et al. Multicenter interventional phase iv study for the assessment of the effects on patient's satisfaction of peg IFN Beta-1a (Pre-filled Pen) in subjects with relapsing-remitting multiple sclerosis unsatisfied with other injectable subcutaneous interferons (PLATINUM Study). Front Neurol 2021; 12: 637615.
  49. Arroyo GR, Kita M, Crayton H, Havrdova E, Margolin DH, Lake SL, et al. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler 2017; 23(10): 1367-76.
  50. Rodgers J, Bland R. Psychiatric manifestations of multiple sclerosis: A review. Can J Psychiatry 1996; 41(7): 441-5.
Current Journal of Neurology

Articles in Press, Accepted Manuscript
Available Online from 13 December 2024
Files
Share
How to cite
Statistics